Would you offer endocrine therapy to a patient with T1c tumor who was initially ER+ (15%)/PR negative/HER2-1+ but changed to a triple negative phenotype after neoadjuvant chemotherapy with TC?

~40% residual tumor at resection with repeat prognostics ER/PR/HER2 all negative. Would you add endocrine therapy to adjuvant capecitabine in this situation?

Please select the option that best describes you:

Would you offer endocrine therapy to a patient with T1c tumor who was initially ER+ (15%)/PR negative/HER2-1+ but changed to a triple negative phenotype after neoadjuvant chemotherapy with TC?

Related Questions